Irsko - angličtina - HPRA (Health Products Regulatory Authority)

menarini international operations luxembourg s.a. - calcium phosphate; cholecalciferol - powder for oral suspension - 1200 mg/800 international unit(s) - calcium, combinations with vitamin d and/or other drugs

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - colecalciferol; calcium phosphate - powder for oral suspension - 1200mg/800 international unit(s) - calcium, combinations with vitamin d and/or other drugs

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

menarini international operations luxembourg s.a. - calcium phosphate; cholecalciferol - powder for oral suspension - 1200mg/800 international unit(s) - calcium, combinations with vitamin d and/or other drugs

Singapur - angličtina - HSA (Health Sciences Authority)

dch auriga singapore - digoxin - injection - 0.5 mg/2 ml - digoxin 0.5 mg/2 ml

Kanada - angličtina - Health Canada

pharmascience inc - digoxin - tablet - 0.0625mg - digoxin 0.0625mg - cardiotonic agents

Kanada - angličtina - Health Canada

pharmascience inc - digoxin - tablet - 0.125mg - digoxin 0.125mg - cardiotonic agents

Kanada - angličtina - Health Canada

pharmascience inc - digoxin - tablet - 0.25mg - digoxin 0.25mg - cardiotonic agents

Malta - angličtina - Medicines Authority

aspen pharma trading limited 3016 lake drive city west businees campus dublin 24, ireland - digoxin - tablet - digoxin 62.5 µg - cardiac therapy

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 250 microgram - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; rice starch; oxidised maize starch; magnesium stearate - congestive heart failure; lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation: because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia: lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Izrael - angličtina - Ministry of Health

perrigo israel agencies ltd - digoxin - solution for injection - digoxin 0.5 mg / 2 ml - digoxin - digoxin - for management of chronic cardiac failure,and certain supraventricular arrhythmias.